Competitive Technologies' Distribution Agreements Now Cover 45% of World Population


CTT Signs New Medical Device Distribution Agreement

FAIRFIELD, Conn., Feb. 24, 2009 (GLOBE NEWSWIRE) -- Competitive Technologies,
Inc. (NYSE Alternext US:CTT) announced today that it has signed an agreement
with Life Episteme srl granting them exclusive distribution rights in each of
29 countries throughout Europe, Asia, Africa, the Middle East, South America
and Oceania for CTT's pain management medical device. The device is a
non-invasive method for rapid treatment of high-intensity oncologic and
neuropathic pain, including pain resistant to morphine and other drugs. 

"We have seen this innovative device successfully used in Italy, and are proud
to be able to bring it to other patients around the world," said Dr. Domenico
Pecorini, one of the founders of Life Episteme. "The population in the
countries included in our contract totals over 1.7 billion people, about 25% of
the world's population. Our network of distributors in strategic centers around
the world will facilitate the delivery process for the device." 

"Life Episteme provides CTT with a strong and effective global partner," said
John B. Nano, CTT's Chairman, President and CEO. "This represents a remarkable
opportunity for our innovative pain management medical device. Our exclusive
signed distribution agreements for this device now cover over 45% of the
world's population and the contractual minimums have a retail sales value of
over $25 million for 2009 and about $50 million for 2010. CTT will share in
revenue derived from sales of the device to our distributors and both CTT and
our distributors expect sales to exceed the contract minimums." 

The CTT device has Medical Device CE certification from the European Union
allowing sales of the device throughout Europe and several other countries. The
review and selection process for additional distributors in other countries is
continuing. Approval of CTT's pending FDA 510(k) medical device application
will authorize U.S. sales of the device. CTT has exclusive worldwide rights to
this patented device. Earlier country-exclusive distribution rights have been
granted to Excel Life Sciences, Inc. for India, to GEOMC Co., Ltd. for Korea,
to AG Healthcare for Malaysia, and to Biogene Pharma Limited for Bangladesh. 

Life Episteme is a healthcare distribution company formed by Dr. Domenico
Pecorini, Vincenzo de Bustis Figarola, and Paolo Pepe for the purpose of
distributing CTT's device. Life Episteme has strong government and
entrepreneurial connections providing access to the healthcare industry in the
multiple countries on their agreement with CTT. 

Vincenzo de Bustis Figarola, co-founder of Life Episteme, added, "We are
creating a partnership with CTT to revolutionize the treatment of pain in many
countries around the world, in line with CTT's strategy of improving
healthcare. Our varied experience in business, finance and technology, enables
us to work with CTT to accomplish this goal in the contract area. 

"This strategic initiative is part of our activity in biotech private equity
that has in great consideration the actual and future exceptional technological
realization of Prof. Marineo. We would pursue economic targets not excluding
social-ethic policies in special arrangements with local governments. The
distribution strategy will benefit the support of Bridge International Advisory
Company, shortly to be transformed in an advisory bank. Bridge will facilitate
the international distribution thanks to its global network arranging local JV
in the single region and organizing the financial support." 

Developed in Italy by CTT's client, Prof. Giuseppe Marineo, the device was
brought to CTT through the efforts of Prof. Giancarlo Elia Valori of the
Italian business development group, Sviluppo Lazio S.p.A., and assistance from
the Zangani Investor Community(tm). The device, with a biophysical rather than
a biochemical approach, uses a multi-processor able to simultaneously treat
multiple pain areas by applying surface electrodes to the skin. CTT partner,
GEOMC Co., Ltd. of Korea, is producing the device commercially for worldwide
distribution. For more information on the device, visit www.CalmareTT.com. 

The device has been used on over 3,000 patients in Europe, including at the
Pain Management Center at Tor-Vergata University Medical Center in Rome
(www.ptvonline.it/uo_ter_ant_ing.asp). 

All the training programs for qualified personnel will be held at Fondazione
Parco Biomedico San Raffaele in Rome (www.scienceparkrome.eu). 

Mr. Nano noted, "We believe that revenue and profits from the pain management
medical device will significantly increase CTT's market capitalization. This
technology is a prime example of our strategy to connect clinical science to
patient care, improving healthcare for mankind." 

About Life Episteme srl

The privately held Life Episteme group based in Rome, Italy, was formed in 2009
as a medical device distribution company. The experience of the co-founders,
Dr. Domenico Pecorini and Vincenzo de Bustis Figarola, have provided the group
with strong relationships in government, business and technology spheres in
various countries around the world. Visit Life Episteme's website. 

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, provides distribution, patent
and technology transfer, sales and licensing services focused on the needs of
its customers and matching those requirements with commercially viable product
or technology solutions. CTT is a global leader in identifying, developing and
commercializing innovative products and technologies in life, electronic, nano,
and physical sciences developed by universities, companies and inventors. CTT
maximizes the value of intellectual assets for the benefit of its customers,
clients and shareholders. Visit CTT's website: www.competitivetech.net 

Statements made about our future expectations are forward-looking statements
and subject to risks and uncertainties as described in our most recent Annual
Report on Form 10-K for the year ended July 31, 2008, filed with the SEC on
October 28, 2008, and other filings with the SEC, and are subject to change at
any time. Our actual results could differ materially from these forward-looking
statements. We undertake no obligation to update publicly any forward-looking
statement. 

CONTACT:  IR Services, LLC
          Johnnie D. Johnson 
          860 434 2465
          jdjohnson@corpirservices.com